BGI Genomics’ Colorectal Cancer Diagnostic Receives CE Mark

May 21, 2021

BGI Genomics has obtained CE mark certification for its DNA Methylation Detection Kit, a test kit for colorectal cancer screening.

The diagnostic uses stool samples to detect abnormal methylation of the SDC2, ADHFE1 and PPP2R5C genes, which are highly specific markers for colorectal cancer cells.

The kit is meant for use as a noninvasive test to help diagnose patients who are recommended for diagnostic colonoscopies by clinicians.

View today's stories